Trastuzumab in the treatment of metastatic breast cancer : anticancer therapy versus cardiotoxicity.
about
Tissue engineering the cardiac microenvironment: Multicellular microphysiological systems for drug screeningInhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivoThe transcription factor GATA-6 regulates pathological cardiac hypertrophyMarked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibitionCardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological preventionTrastuzumab Administration in Patients with Metastatic Breast Cancer - Experience of a Large University Breast CenterTrastuzumab-induced cardiotoxicity: testing a clinical risk score in a real-world cardio-oncology population.Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?ErbB signaling in cardiac development and disease.Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy.Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity.Building better monoclonal antibody-based therapeutics.Cardiac sympathetic hyperactivity after chemotherapy: early sign of cardiotoxicity?The experience of a multidisciplinary clinic in the management of early-stage breast cancer patients receiving trastuzumab therapy: an observational study.Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity.Late administration of murine CTLA-4 blockade prolongs CD8-mediated anti-tumor effects following stimulatory cancer immunotherapy.Role of anthracyclines in the era of targeted therapy.The emerging role of pharmacogenomics in biologics.Trastuzumab and doxorubicin-related cardiotoxicity and the cardioprotective role of exercise.Cardiovascular safety and hemodynamic considerations in oncology drug development - webinar highlights October 10th 2012.Molecular basis of cancer-therapy-induced cardiotoxicity: introducing microRNA biomarkers for early assessment of subclinical myocardial injury.Update on cardiotoxicity of anti-cancer treatments.Spironolactone ameliorates the cardiovascular toxicity induced by concomitant trastuzumab and thoracic radiotherapy.Oncocardiology-Past, Present, and Future: A Review.Valvular Heart Disease in Cancer Patients: Etiology, Diagnosis, and Management.Radiation- and anthracycline-induced cardiac toxicity and the influence of ErbB2 blocking agents.Heterozygous knockout of neuregulin-1 gene in mice exacerbates doxorubicin-induced heart failure.Effects of neuregulin-1 on autonomic nervous system remodeling post-myocardial infarction in a rat model.Cardiac Nonmyocyte Cell Functions and Crosstalks in Response to Cardiotoxic Drugs.Whole exome sequencing to identify genetic markers for trastuzumab-induced cardiotoxicity.Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin).Trastuzumab therapy and the heart: palliation at what cost?Echocardiography signs of early cardiac impairment in patients with breast cancer and trastuzumab therapy.α-Tocopheryloxyacetic acid is superior to α-tocopheryl succinate in suppressing HER2-high breast carcinomas due to its higher stability
P2860
Q26799470-FA5DDC93-CFC8-4D21-B25C-9E71FEBFAD5BQ28188254-187FBE18-9616-4BD0-BD96-505F59E87F69Q28512555-10C80F7D-95C7-4747-A6F5-FE5D3D7F596FQ28829301-743B5BCF-33ED-48B2-98EB-782C404DB981Q33574045-F3D1B655-1823-48A3-9C82-A0C2EAD33EFDQ33800955-4782638E-B33F-4F13-BB79-6C1E1E4C57D9Q33840140-A06C4796-25F1-42E7-98DC-2CABD7B5F4EEQ34102834-0C51A800-812D-476B-AC3D-B302ACB57B01Q34545577-372A3D72-983C-4997-929B-F8C4AC850C02Q35020538-2482A010-9F76-4968-B687-591CC282EE88Q35035923-1DE6B650-3D03-4B42-833E-E4E6362CBFB2Q35817552-7C2C2196-CB82-4C11-B597-EADDF169E2B2Q36117002-8AD2D2D0-09F0-46D6-BC6B-D04793F6AC27Q36294169-5077849E-F50C-405A-8AD8-283631B5992EQ36637796-32670309-063C-4287-A77B-A159C48CFA6AQ36663524-6BC7D507-1337-427C-AE06-F53E0E295E14Q36891697-8F0FCDCE-78DE-4C5A-9595-DBEE32932FBCQ36916630-2ED067A1-644D-4408-8322-26DE9ECF1432Q37378906-3790F787-CAD3-4FA9-ABA2-7B8646360353Q38104812-80FD7AD3-D8A0-4CCA-BB3F-E2429B31563AQ38166071-76625AD5-27EA-42FE-A4DA-70F883E6554AQ38686222-35CA7909-A6F6-476A-96AD-A3926E5FB0FCQ38784568-6E93DC9A-D037-43EF-948C-365A6D2C82A2Q38829737-4BAADE49-54E7-41D8-8094-701C552FFC6AQ39332072-14ED485D-F053-4119-A7D5-1D42426D0D21Q42911854-C31C0C7B-E3DD-4BC4-92C1-7B40F96D37C5Q46440272-E808D58D-E695-4406-9168-D68981475B83Q47124548-878D93BF-ACF5-4B96-951B-D75259E9EF80Q47149101-A8BB0A00-FC9A-479F-B608-5EA5C182305FQ47286758-0992A6CA-E19A-43A2-A7FC-7B6DD4E71AEEQ47323865-55C5A461-4034-4A82-9406-7E87820D3246Q47572376-954BA159-9CEF-4EAF-9E9B-589927B3F219Q51367703-5B069445-E04B-4E6C-89B2-69F285EDE12EQ57649939-5FA4333B-AEA8-46BC-9601-7D238CB2B484
P2860
Trastuzumab in the treatment of metastatic breast cancer : anticancer therapy versus cardiotoxicity.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Trastuzumab in the treatment o ...... therapy versus cardiotoxicity.
@ast
Trastuzumab in the treatment o ...... therapy versus cardiotoxicity.
@en
type
label
Trastuzumab in the treatment o ...... therapy versus cardiotoxicity.
@ast
Trastuzumab in the treatment o ...... therapy versus cardiotoxicity.
@en
prefLabel
Trastuzumab in the treatment o ...... therapy versus cardiotoxicity.
@ast
Trastuzumab in the treatment o ...... therapy versus cardiotoxicity.
@en
P2093
P356
P1433
P1476
Trastuzumab in the treatment o ...... therapy versus cardiotoxicity.
@en
P2093
P304
P356
10.1161/01.CIR.102.3.272
P407
P577
2000-07-01T00:00:00Z